Incyte Corporation
A biopharmaceutical company that develops treatments for blood cancers and other cancers (JAKAFI, ICLUSIG), plus creams for skin conditions like vitiligo and eczema (OPZELURA). Founded in 1991 in Palo Alto, it began as a genomics pioneer selling its LifeSeq gene database to researchers before pivoting to making its own drugs. Its name blends "insight" with "cyt," the Greek root for cell — a nod to its genome-sequencing roots.
Granted 15.56M · Bought 4.10M
Granted 273.1K · Bought 4.11M
Granted 1.85M · Bought 8.45M · Sold 1.42M
Granted 15.0K
Bought 891.3K
Bought 2.23M
Bought 887.1K · Sold 554.0K
Granted 30.0K
Granted 95.0K · Sold 375.3K
Granted 101.5K · Bought 224.3K · Sold 44.9K
Granted 1.19M · Bought 27.9K · Sold 471.9K
Granted 166.9K · Bought 50.0K · Sold 25.0K
Bought 5.9K
Granted 2.51M · Bought 95.2K · Sold 2.46M
Granted 327.0K · Sold 56.0K
Bought 5.5K · Sold 45.2K
Bought 70.5K
Granted 161.1K
Granted 50.3K · Bought 34.3K · Sold 30.2K
Granted 162.2K
Granted 427.6K · Bought 8.0K · Sold 465.3K
Granted 360.0K · Bought 10.0K · Sold 360.0K
Granted 1.31M · Bought 3.0K · Sold 1.19M
Bought 19.0K
Granted 225.0K · Bought 45.0K · Sold 190.0K
Granted 321.1K · Sold 222.0K
Granted 450.8K · Sold 257.7K
Granted 196.6K · Sold 109.1K
Granted 85.3K · Sold 10.9K
Granted 155.8K · Sold 110.0K
Sold 5.8K
Granted 93.5K · Sold 21.3K
Granted 166.3K · Sold 99.0K
Sold 22.0K
Granted 41.7K · Sold 3.1K
Granted 36.3K · Sold 24.8K
Granted 278.0K · Sold 196.0K
Granted 122.1K · Sold 93.7K
Granted 295.0K · Bought 4.5K · Sold 295.0K
Granted 73.7K · Sold 78.3K
Granted 123.3K · Sold 96.3K
Granted 60.1K · Sold 28.2K
Granted 26.3K
Granted 40.4K · Sold 15.0K
Granted 35.5K · Bought 4.5K · Sold 2.5K
Granted 28.0K · Sold 17.9K
Granted 22.8K
Granted 330.4K · Sold 310.4K
Granted 21.0K
Granted 846.9K · Sold 830.0K
Granted 103.6K · Bought 7.5K · Sold 93.3K
Granted 15.0K
Granted 15.7K
Granted 363.7K · Sold 360.7K
Granted 12.9K
Granted 6.5K
Granted 89.6K · Sold 72.9K
Granted 9.5K
Granted 9.4K
Granted 775.0K · Bought 8.5K · Sold 775.0K
Granted 9.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP +6 co-filersDirector, 10% owner · 150 transactions | — | 126.46Mas of Jun 2019 | 15.56M | 4.10M | — |
| Baker Bros. Advisors LP +5 co-filersDirector, 10% owner · 121 transactions | — | 121.83M | 273.1K | 4.11M | — |
| Baker Felix +2 co-filersDirector, 10% owner · 60 transactions | — | 12.32Mas of Jan 2012 | 1.85M | 8.45M | 1.42M |
| Baker JulianDirector, 10% owner · 6 transactions | — | 5.55Mas of Aug 2012 | 15.0K | — | — |
| Baker Julian +1 co-filerDirector, 10% owner · 30 transactions | — | 4.57Mas of Dec 2007 | — | 891.3K | — |
| Baker Julian +1 co-filerDirector, 10% owner · 26 transactions | — | 4.28Mas of Dec 2007 | — | 2.23M | — |
| Baker Felix +2 co-filersDirector, 10% owner · 27 transactions | — | 2.93Mas of Sep 2010 | — | 887.1K | 554.0K |
| Baker Bros Advisors LLC +5 co-filersDirector, 10% owner · 3 transactions | — | 2.57Mas of Jun 2013 | 30.0K | — | — |
| Whitfield Roy ADirector · 131 transactions | — | 666.1Kas of Dec 2013 | 95.0K | — | 375.3K |
| Baker Felix +2 co-filersDirector, 10% owner · 57 transactions | — | 352.8Kas of Jan 2012 | 101.5K | 224.3K | 44.9K |
| Hoppenot HerveDirector · 60 transactions | — | 326.8K | 1.19M | 27.9K | 471.9K |
| Brooke Paul ADirector · 39 transactions | — | 301.9Kas of Apr 2020 | 166.9K | 50.0K | 25.0K |
| Baker Julian +1 co-filerDirector, 10% owner · 27 transactions | — | 278.9Kas of Dec 2007 | — | 5.9K | — |
| Friedman Paul ADirector · 95 transactions | — | 271.8Kas of May 2020 | 2.51M | 95.2K | 2.46M |
| Cagnoni Pablo JPresident, Global Head of R&D · 18 transactions | — | 240.8K | 327.0K | — | 56.0K |
| Baker Felix +2 co-filersDirector, 10% owner · 27 transactions | — | 227.6Kas of Jun 2011 | — | 5.5K | 45.2K |
| Baker Julian +1 co-filerDirector, 10% owner · 26 transactions | — | 187.1Kas of Dec 2007 | — | 70.5K | — |
| Meury WilliamChief Executive Officer, Director, President · 2 transactions | — | 161.1K | 161.1K | — | — |
| Baker Felix +2 co-filersDirector, 10% owner · 27 transactions | — | 159.7Kas of Sep 2010 | 50.3K | 34.3K | 30.2K |
| Stamoulis ChristianaEVP & Chief Financial Officer · 33 transactions | — | 125.8Kas of Jul 2025 | 162.2K | — | — |
| Chardonnet LaurentVice President and Treasurer · 69 transactions | — | 116.5Kas of Mar 2015 | 427.6K | 8.0K | 465.3K |
| Metcalf Brian WChief Drug Discovery Scientist · 22 transactions | — | 116.5Kas of Apr 2011 | 360.0K | 10.0K | 360.0K |
| Swain Paula JEVP, Human Resources · 145 transactions | — | 106.5Kas of Jul 2025 | 1.31M | 3.0K | 1.19M |
| Baker Julian +1 co-filerDirector, 10% owner · 24 transactions | — | 105.0Kas of Dec 2007 | — | 19.0K | — |
| De Schutter Richard UReporting owner · 20 transactions | — | 99.8Kas of Mar 2015 | 225.0K | 45.0K | 190.0K |
| Wenqing YaoEVP, Head of Discovery Chem · 76 transactions | — | 98.6Kas of Jul 2021 | 321.1K | — | 222.0K |
| Stein Steven HCMO & Head of Late-Stage Dev. · 101 transactions | — | 78.3K | 450.8K | — | 257.7K |
| Pasquale Maria EEVP & General Counsel · 77 transactions | — | 69.7Kas of Jul 2023 | 196.6K | — | 109.1K |
| Issa Mohamed KhairieEVP, Head of US Oncology · 5 transactions | — | 66.1K | 85.3K | — | 10.9K |
| Ariko Barry ADirector · 13 transactions | — | 65.8Kas of Mar 2015 | 155.8K | — | 110.0K |
| Mayes Patrick AEVP & Chief Scientific Officer · 3 transactions | — | 60.0K | — | — | 5.8K |
| Dhanak DashyantEVP & Chief Scientific Officer · 52 transactions | — | 59.0Kas of Jul 2023 | 93.5K | — | 21.3K |
| Iyengar Vijay KEVP, GMAPPS · 67 transactions | — | 40.5Kas of Jul 2025 | 166.3K | — | 99.0K |
| Friedman Steven M.EVP, Biology & Preclinical Dev · 1 transaction | — | 38.1Kas of Jan 2010 | — | — | 22.0K |
| Heeson LeeEVP, Head of Incyte Intl · 6 transactions | — | 38.0K | 41.7K | — | 3.1K |
| Dickinson Jonathan ElliottEVP, General Manager, Europe · 28 transactions | — | 36.4Kas of Sep 2024 | 36.3K | — | 24.8K |
| Flannelly Barry PEVP & General Manager US · 96 transactions | — | 35.1Kas of Jul 2025 | 278.0K | — | 196.0K |
| Huber Reid MEVP, Chief Scientific Officer · 39 transactions | — | 34.6Kas of Jul 2018 | 122.1K | — | 93.7K |
| Schreck Patricia AEVP, General Counsel · 27 transactions | — | 34.5Kas of May 2011 | 295.0K | 4.5K | 295.0K |
| Morrissey Michael JamesEVP, Head of Tech. Operations · 38 transactions | — | 34.1K | 73.7K | — | 78.3K |
| Trower PaulPrincipal Accounting Officer · 57 transactions | — | 32.3Kas of Jan 2022 | 123.3K | — | 96.3K |
| Denton Sheila A.EVP & General Counsel · 35 transactions | — | 26.6K | 60.1K | — | 28.2K |
| Upadhyay SuketuEVP & Chief Financial Officer · 1 transaction | — | 26.3K | 26.3K | — | — |
| Clancy Paul JDirector · 39 transactions | — | 25.4K | 40.4K | — | 15.0K |
| Bienaime Jean JacquesDirector · 43 transactions | — | 24.4K | 35.5K | 4.5K | 2.5K |
| Tray ThomasPrincipal Accounting Officer · 33 transactions | — | 23.8K | 28.0K | — | 17.9K |
| Harrigan EdmundDirector · 34 transactions | — | 22.8K | 22.8K | — | — |
| Siegel Eric H.EVP, General Counsel · 104 transactions | — | 21.1Kas of Sep 2017 | 330.4K | — | 310.4K |
| Fouse Jacqualyn ADirector · 28 transactions | — | 21.0K | 21.0K | — | — |
| Levy Richard SEVP, Chief Drug Dev Officer · 89 transactions | — | 20.9Kas of Jan 2016 | 846.9K | — | 830.0K |
| Dixon Wendy LDirector · 47 transactions | — | 17.8Kas of Mar 2022 | 103.6K | 7.5K | 93.3K |
| High Katherine ADirector · 8 transactions | — | 15.0K | 15.0K | — | — |
| Trotta MatteoEVP, GM, Dermatology US · 6 transactions | — | 14.9K | 15.7K | — | — |
| Daly James MEVP, Chief Commercial Officer · 69 transactions | — | 14.2Kas of Jun 2015 | 363.7K | — | 360.7K |
| Brawley Otis WDirector · 6 transactions | — | 12.9K | 12.9K | — | — |
| Basi Ramitpal KEVP, Human Resources · 2 transactions | — | 11.0K | 6.5K | — | — |
| Gryska David WExecutive Vice President, CFO · 24 transactions | — | 10.2Kas of Jul 2018 | 89.6K | — | 72.9K |
| Hoffman Richard A.EVP & General Counsel · 1 transaction | — | 9.5K | 9.5K | — | — |
| Gardner David HEVP, Chief Strategy Officer · 1 transaction | — | 9.4K | 9.4K | — | — |
| Hastings David CChief Financial Officer · 37 transactions | — | 8.5Kas of Jun 2014 | 775.0K | 8.5K | 775.0K |
| Schaffert SusanneDirector · 7 transactions | — | 4.9Kas of Jun 2025 | 9.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +9.45M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.